LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Akcijų sąrašas・Erasca Inc

Erasca Inc

Uždarymo kaina

10.85 8.5

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

9.81

Max

10.92

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1.5M -29M
Darbuotojai	103
EBITDA	-2M -32M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+99.21% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1.7B 3.2B
Ankstesnė atidarymo kaina	2.35
Ankstesnė uždarymo kaina	10.85

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.39 / 1.44 Palaikymas ir pasipriešinimas

Erasca Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-06 23:41; UTC

Uždarbis

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

2026-05-06 21:40; UTC

Uždarbis

Nutrien Logs Higher Profit, Sales Growth in 1Q

2026-05-06 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

2026-05-06 23:34; UTC

Rinkos pokalbiai

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

2026-05-06 23:13; UTC

Uždarbis

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

2026-05-06 23:13; UTC

Uždarbis

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

2026-05-06 23:12; UTC

Uždarbis

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

2026-05-06 23:11; UTC

Uždarbis

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

2026-05-06 23:07; UTC

Uždarbis

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

2026-05-06 23:06; UTC

Uždarbis

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

2026-05-06 23:06; UTC

Uždarbis

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

2026-05-06 23:05; UTC

Uždarbis

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

2026-05-06 23:04; UTC

Uždarbis

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

2026-05-06 22:50; UTC

Uždarbis

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

2026-05-06 22:25; UTC

Rinkos pokalbiai

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

2026-05-06 22:11; UTC

Uždarbis

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

2026-05-06 22:11; UTC

Uždarbis

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

2026-05-06 22:05; UTC

Rinkos pokalbiai

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

2026-05-06 21:58; UTC

Uždarbis

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

2026-05-06 21:47; UTC

Rinkos pokalbiai

Uždarbis

Costco Posts 13% Sales Growth in April -- Market Talk

2026-05-06 21:46; UTC

Uždarbis

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

2026-05-06 21:40; UTC

Uždarbis

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

2026-05-06 21:35; UTC

Rinkos pokalbiai

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

2026-05-06 21:32; UTC

Karštos akcijos

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

2026-05-06 21:29; UTC

Uždarbis

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Erasca Inc Prognozė

Kainos tikslas

By TipRanks

99.21% į viršų

12 mėnesių prognozė

Vidutinis 20.2 USD 99.21%

Aukščiausias 30 USD

Žemiausias 9 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Erasca Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Erasca Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.39 / 1.44Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.